A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
MOMA Therapeutics
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Revolution Medicines, Inc.
USWM, LLC (dba US WorldMeds)
ARTBIO Inc.
Modulation Therapeutics, Inc.
Pfizer
Erasca, Inc.
Novartis
National Cancer Institute (NCI)
GlaxoSmithKline
Daiichi Sankyo
Mayo Clinic
The Methodist Hospital Research Institute
Boehringer Ingelheim
Tomsk National Research Medical Center of the Russian Academy of Sciences
Daiichi Sankyo
National Cancer Institute (NCI)
AstraZeneca
EMD Serono
Genentech, Inc.
Werewolf Therapeutics, Inc.
ModernaTX, Inc.
EMD Serono
Peptomyc S.L.
M.D. Anderson Cancer Center
University of Washington
Royal Marsden NHS Foundation Trust
Merck Sharp & Dohme LLC
Pierre Fabre Medicament
ImmunityBio, Inc.
University Health Network, Toronto
Chinese PLA General Hospital
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
University of Kansas Medical Center
Turning Point Therapeutics, Inc.
M.D. Anderson Cancer Center